The program of Medicines Essential and Logistics Support Center (Promise/CAL) completed this Friday the process of award of the last batch of drugs required by the Directorate of Access to Medicines of High price (Damac) of the Ministry of Public Health.
“Were 70 molecules awardedwhich come to complement a first purchase managed last May,” he said. Promise/CAL.
The molecules refer to the active components of each drugsince the trade name varies depending on the laboratory that manufactures it.
With this purchase, the needs of almost 15 thousand patients assigned to the program, for the remaining months of this year 2022.
The entity assured that the medicines purchased through the first tender They have been delivered to the warehouses of the Ministry of Public Health and those of the second will begin to be distributed in the coming days.
Promise/CAL explained that one of the molecules, the bendamustine hydrochloride 100 mg/vialan anticancer used to treat chronic lymphocytic leukemia and certain types of non-Hodgkin’s lymphoma, was left out due to no bidding, but it will be launched again next week.
Government investment in the last year in medicines of high price It is 7,200 million pesos.
In all this process, Promise/CAL It acts as a purchasing center, which it carries out according to the requirements and specifications of Damac, which is the entity in charge of administering the program.
The purchase of medicines high price was part of the opening of 1,903 economic proposals for the acquisition of medicines and health supplies to supply the network of Farmacias del Pueblo and the National Health System, including others medicines and expendable materials, other than the products of high price.
About the awards
The acquisition of medicines of high price was divided into two games: a first purchase of the 27 most demanded compounds and a second award with the remaining 70 products.
With an investment of 3,438 million pesos, only for medicines of high price, The awards will begin to be delivered to the Public Health warehouses in August.
“Last May we received the purchase list, the technical sheets and the budget appropriation, and since then, we have worked quickly to meet the request, always respecting the times and indications established in the Purchasing and Contracting Law 340-06”, said the director of Promise/CAL, Adolfo Perez.
Between the medicines from the first game, molecules for various ailments stand out:
Glatiramer acetate, fingolimod and teriflinomide for patients with multiple sclerosis.
For the transplant patients: Cyclosporine, Everolimus, Mycophenolate sodium and mofetil; sirolumus and tacrolimus.
For patients with different types of cancer: Fulvestrant, Palbociclib, Ribociclib, Trastuzumab, Goserelin Acetate, among others.
In the second game, Tocilizumab stands out, a monoclonal antibody in great demand in severe COVID-19 patients.
The list also includes Ibrutinib, a treatment kinase inhibitorenzyme that promotes cell proliferation, thus preventing the multiplication of cancer cells in the body.
